[HTML][HTML] TGF-beta-activated cancer-associated fibroblasts limit cetuximab efficacy in preclinical models of head and neck cancer
Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against
the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in …
the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in …
[HTML][HTML] MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer
M Prasad, J Zorea, S Jagadeeshan… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
Background Although the mitogen-activated protein kinases (MAPK) pathway is hyperactive
in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown …
in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown …
[HTML][HTML] Tumor tissue explant culture of patient-derived xenograft as potential prioritization tool for targeted therapy
Despite of remarkable progress made in the head and neck cancer (HNC) therapy, the
survival rate of this metastatic disease remain low. Tailoring the appropriate therapy to …
survival rate of this metastatic disease remain low. Tailoring the appropriate therapy to …
[HTML][HTML] IGF2 mediates resistance to isoform-selective-inhibitors of the PI3K in HPV positive head and neck cancer
Simple Summary In the current study, we delineate the molecular mechanisms of acquisition
of resistance to two isoform-selective inhibitors of PI3K (isiPI3K), alpelisib and taselisib, in …
of resistance to two isoform-selective inhibitors of PI3K (isiPI3K), alpelisib and taselisib, in …